Actinium Pharmaceuticals
ATNM
56 hedge funds and large institutions have $21.2M invested in Actinium Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 8 reducing their positions, and 5 closing their positions.
138% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 8
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
78% more capital invested
Capital invested by funds: $11.9M → $21.2M (+$9.31M)
55% more call options, than puts
Call options by funds: $3.44M | Put options by funds: $2.23M
12% more funds holding
Funds holding: 50 → 56 (+6)
1.01% more ownership
Funds ownership: 10.4% → 11.42% (+1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$925K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$561K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$261K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$248K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$173K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$272K |
| 2 |
Two Sigma Investments
New York
|
-$257K |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$151K |
| 4 |
VF
Virtu Financial
New York
|
-$144K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$76.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CSS
51
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$151K | -31,484 | Closed |
|
|
TSS
52
Two Sigma Securities
New York
| – | -$61K | -12,624 | Closed |
|
|
BCV
53
Banque Cantonale Vaudoise
Lausanne,
Switzerland
| – | -$1K | -309 | Closed |
|
54
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -166 | Closed |
|
|
AIM
55
Axiom Investment Management
New York
| – | +$31 | +5 | New |
|
56
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$354 | +57 | New |
|
ATNM Hedge Fund Activity: Q3 2022 in Review
56 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q3 2022, worth a combined $21.2M — up 78% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ATNM positions and 5 closed out — a net gain of 6 holders — while 19 added to existing stakes and 8 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $925K. The largest seller was Susquehanna International Group, cutting an estimated $272K.
- 56 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q3 2022, up from 50 in Q2 2022.
- Funds reported $21.2M of Actinium Pharmaceuticals stock for Q3 2022, up 78% quarter-over-quarter.
- 11 funds opened new Actinium Pharmaceuticals positions in Q3 2022 and 5 closed out, a net change of +6 holders.
- The largest Actinium Pharmaceuticals buyer in Q3 2022 was J. Goldman & Co, an estimated $925K added.
- The largest Actinium Pharmaceuticals seller in Q3 2022 was Susquehanna International Group, an estimated $272K sold.
Based on aggregated 13F filings for Q3 2022.